AstraZeneca and Daiichi Sankyo receive conditional approval for Enhertu in China

AstraZeneca and Daiichi Sankyo have been granted conditional approval by Chinese regulators for a new indication of their cancer therapy Enhertu. The approval is expected to broaden patient access to the treatment in the Chinese market.

Detected & updated continuously · Source: Nebula